[676] in Locker Maintainers
Please watch this penny stock trade
daemon@ATHENA.MIT.EDU (The Bull)
Thu Jan 20 07:37:05 2005
Date: Thu, 20 Jan 2005 16:29:51 +0400 (CST)
Message-Id: <50522986173207.x72ENIsiiQB508@trademark157.drapery92bright.net>
To: locker-maintainers@mit.edu
From: The Bull <zvnyyvzo@myexcel.com>
MIME-Version: 1.0
Content-Type: multipart/alternative;
boundary="--xgndog5489071769594536vvn"
----xgndog5489071769594536vvn
Content-Type: text/plain;
Content-Transfer-Encoding: quoted-printable
Bio-Matrix Scientific Group, Inc.
Symbol: OTC Pink Sheets: BMXG.PK
Industry: Biotechnology; Stem Cell Technologies
Current Price: 0.40
Projected Valuation: 3.50 per share
About the Company:
Bio-Matrix Scientific Group, Inc. is an innovative biotechnology R&D compa=
ny, focused on the commercialization of new and groundbreaking stem cell t=
echnologies. The Company has focused its initial efforts on the launch of=
an innovative adult cryogenic stem cell bank which will store stem cell t=
issues for use in treatment of future diseases and ailments. The Company =
plans to launch its initial cryogenic stem cell facilities in mid-2005, an=
d is additionally exploring opportunities for commercialization of new tec=
hnologies in tissue management, stem cell research instrumentation, and bi=
o-systems monitoring. With impending establishment of an adult stem cell =
cryobank, research efforts at the forefront of the stem cell market, and e=
xperienced management team, we could see Bio-Matrix Scientific Group emerg=
e as the newest and most dynamic player in the explosive stem cell researc=
h market.
Investment Highlights:
Bio-Matrix Scientific is exceptionally well positioned at the forefront of=
one of the most exciting new frontiers in biotechnology- stem cell resear=
ch, which has exploded since its inception a mere twenty years ago as a pa=
nacea for the treatment of degenerative disease. While stem cell therapy =
is still a relatively new concept, expectations are almost universally pos=
itive, with research firm visiongain predicting that stem cell product rev=
enues will exceed 10 billion by 2013. Recently, voters in California over=
whelmingly approved passage of Proposition 71, a landmark piece of legisla=
tion which provides 3 billion in stem cell funding over the next ten years=
, and will stimulate a stem cell research boom throughout the state.
With its initial focus on the establishment of stem cell cryogenic storage=
facilities, Bio-Matrix is additionally well situated in a rapidly growing=
and commercially successful market. Until recently, this market has been=
primarily limited to the cryogenic storage of cord blood tissues, used ma=
inly for bone marrow transplant procedures. There are over 10 major cord =
blood banks in the world, preserving cells from more than 35,000 donors wi=
th average fees of 20,000 per patient- representing a total current market=
of over 720 million. As the public understanding of stem cells increases=
, and as additional stem cell therapies are developed, we believe that thi=
s niche market will enjoy exponential growth. As it is the foremost stem =
cell banker focusing on the storage of adult stem cells, an unexplored but=
lucrative market, we believe that Bio-Matrix stands to enjoy tremendous r=
evenue growth in the near-term period.
The Company benefits from a surprisingly strong (for a Pink Sheets Company=
) and experienced management team, who have combined financial acumen with=
scientific savvy to offer a unique and promising model for growth in the =
stem cell market. The Company=92s senior management team, helmed by David=
Koos, PhD a 20 year veteran of investment banking, has extensive experien=
ce in capital financing and public company management, while its research =
efforts under the guidance of Dr. Philip Watts (PhD- Caltech) are intimate=
ly involved in the newest academic research into stem cell technologies.
Based solely on its stem cell cryogenic storage service, and without consi=
dering the potential top line impact of the Company=92s efforts in tissue =
management, stem cell instrumentation, and bio-systems monitoring, we anti=
cipate tremendous revenue growth for Bio-Matrix Scientific Group. With la=
unch of its stem cell cryobank in mid-late 2005, we anticipate FY 2005 sal=
es of approximately 3.5 million, growing to over 24.7 million in 2006 and =
35 million in 2007 as medically-conscious consumers seek to avail themselv=
es of the promise of stem cell technologies.
Relative to a peer grouping of companies engaged in the stem cell research=
and cryogenic tissue storage industries, who trade at an average price to=
sales multiple of 8x, Bio-Matrix Scientific Group is prices at a steep di=
scount given its technology suite, management team, and sales expectations=
By applying this comparative grouping=92s average P/R multiple to the C=
ompany=92s expected FY 2005 RPS of 0.44, we can arrive at a relative valua=
tion for Bio-Matrix of approximately 3.50 per share- a premium of almost 1=
000% from current levels.
From the Investor's Point of View: How arrived at our conclusions for BMXP=
:
A peer grouping of comparative stem cell storage and tissue management com=
panies currently trades at an average price to revenue multiple of 8x. We=
anticipate that Bio-Matrix Scientific Group, Inc. will distinguish itself=
from these comparative companies with superior financial performance and =
revenue growth. Therefore, on a forward looking basis and applying the co=
mparative grouping=92s average price to sales ratio to the Company=92s ant=
icipated FY 2005 revenues, we can therefore arrive at a relative valuation=
for Bio-Matrix of approximately 3.50 per share; a nearly 10-fold increase=
from current trading levels.
This publication is an independent publication with the goal of giving inv=
estors the necessary knowledge to make rational and profitable investment =
decisions. Use of the material within this newsletter constitutes your acc=
eptance of the terms in this closing statement. This publication does not =
provide an analysis of the Company's financial position and is not an soli=
citation to purchase or sell securities Investing in securities is specula=
tive and carries risk. It is advisable that any investment should be made =
after consulting with your investment expert and after reviewing the finan=
cial statements of the company. The information in this report is believed=
to be reliable, but its accuracy cannot be assured. Past performance does=
not insure similar future results. This is not purported to be a complete=
and thorough analysis of the featured company and recommends a complete r=
eview of the Company's regulatory filings at secgov The information herein=
contains future looking statements and information within the meaning of =
Section 27A of the Securities Act of 1933 and Section 21E of the Securitie=
s Exchange Act of 1934, including statements regarding expected continual =
growth of the featured company. Any statements that express or involve dis=
cussions with respect to predictions, expectations, beliefs, plans, projec=
tions, objectives, goals, assumptions or future events or performance are =
not statements of historical fact and may be future looking statements. Fu=
ture looking statements are based on expectations, estimates and projectio=
ns at the time the statements are made that involve a number of risks and =
uncertainties which could cause actual results or events to differ materia=
lly from those presently anticipated. Future looking statements in this ac=
tion may be identified through the use of words such as projects, foresee,=
expects, will, anticipates, estimates, believes, understands, or that by =
statements indicating certain actions may, could, or might occur. Be aware=
of an inherent conflict of interest resulting from such compensation due =
to the fact that this is a paid publication. All factual information in th=
is report was gathered from public sources, including but not limited to C=
ompany Web sites, SEC filings and Company Press Releases. This information=
is believed to be reliable but can make no absolute certainty as to its a=
ccuracy or completeness. As with many microcap stocks, todays company has =
additional risk factors worth noting. Those factors may include an accumul=
ated deficit since its inception, a negative net worth, reliance on loans =
from officers, directors and a majority shareholder to pay expenses, nomin=
al cash and the need to raise capital. The company may have a going concer=
n opinion from its auditor. In compliance with Section 17b, the publisher =
discloses the holding of two hundred thousand shares of BMXG prior to the =
publication of this report. Be aware of an inherent conflict of interest r=
esulting from such holdings due to the publisher's intent to gain from the=
liquidation of these shares. Shares may be sold at any time, even after p=
ositive statements have been made regarding the above company.
----xgndog5489071769594536vvn--
